-transparent.png){kind=logo}
Beta-receptor blocking drugs are known to decrease BP and plasma renin activity (PRA) in hypertensive patients. We treated 31 hypertensive patients with the beta-receptor blocking drug, pindolol, for 3 months. During the first month (mean daily dose 10 mg) and the second month (mean daily dose 14.2 mg) BP and PRA decreased. During the third month of pindolol therapy (mean daily dose 19.0 mg) 16 patients had an unexpected rise of BP towards control levels and PRA levels rose, too. The remaining 15 patients maintained a good antihypertensive drug effect and suppression of PRA. Pretreatment PRA was not related to BP reduction. The change in diastolic BP was not significantly related to that in PRA. The results indicate that low doses of pindolol,10-15 mg daily, will suffice in mild essential hypertension. An increasing frequency of partial drug resistance may be a result of unnecessarily high doses of pindolol.
F Fyhrquist, and
K Kurppa, and
M Huuskonen, and
A Koistinen
August 1982,
American heart journal,
F Fyhrquist, and
K Kurppa, and
M Huuskonen, and
A Koistinen
June 1976,
Schweizerische medizinische Wochenschrift,
F Fyhrquist, and
K Kurppa, and
M Huuskonen, and
A Koistinen
November 1974,
The American journal of cardiology,
F Fyhrquist, and
K Kurppa, and
M Huuskonen, and
A Koistinen
June 1976,
British journal of clinical pharmacology,
F Fyhrquist, and
K Kurppa, and
M Huuskonen, and
A Koistinen
January 1981,
Journal of clinical pharmacology,
F Fyhrquist, and
K Kurppa, and
M Huuskonen, and
A Koistinen
April 1986,
Journal of clinical pharmacology,
F Fyhrquist, and
K Kurppa, and
M Huuskonen, and
A Koistinen
January 1976,
Acta medica Scandinavica. Supplementum,
F Fyhrquist, and
K Kurppa, and
M Huuskonen, and
A Koistinen
January 1981,
Journal of cardiovascular pharmacology,
F Fyhrquist, and
K Kurppa, and
M Huuskonen, and
A Koistinen
January 1976,
Advances in clinical pharmacology,
F Fyhrquist, and
K Kurppa, and
M Huuskonen, and
A Koistinen
December 1984,
Biochemical Society transactions,
